

# Effect of Estrogen on Bronchiolar Smooth Muscle and Peri-Bronchial Lymphocytic Infiltration in Adult Male Mice

MAMOONA SHAFIQ<sup>1</sup>, AMNA FARUQI<sup>2</sup>, QURATULAIN ZIA<sup>3</sup>, ERUM AFAQ<sup>4</sup>, SADIA MUBARAK<sup>5</sup>, TOOBA ZAFAR<sup>6</sup>

<sup>1</sup>Professor & HOD, Department of Physiology, Islam Medical College, Sialkot

<sup>2,5</sup>Associate Professors, <sup>6</sup>Assistant Professor, Department of Physiology, Islamabad Medical & Dental College, Islamabad

<sup>3</sup>Assistant Professor, Department of Biochemistry, Islamabad Medical & Dental College, Islamabad

<sup>4</sup>Associate Professor, Department of Physiology, Dow Medical College, Dow University of Health Sciences, Karachi

Correspondence to: Mamoonah Shafiq, Email: [dr\\_mamoonah78@hotmail.com](mailto:dr_mamoonah78@hotmail.com), Cell: 0333-3021594

## ABSTRACT

**Objective:** To study the effect of estrogen on lungs of adult male mice by assessing and comparing the following histological parameters including bronchiolar smooth muscle size and peri-bronchial lymphocytic infiltration.

**Study Design:** Randomized control trial

**Place and Duration of Study:** National Institute of Health Sciences, Islamabad from 1<sup>st</sup> October 2018 to 31<sup>st</sup> July 2019.

**Methodology:** Ninety BALB/c mice divided into 2 groups (n=30 per group) were enrolled. The control (male) group received only distilled water, while the interventional groups received pills (estradiol valerate) mixed in distilled water according to body weight of the mice for (60) day.

**Results:** 10% of the total mice had nil, 60% had mild, 30% of the total showed moderate while no severe peri-bronchiolar lymphocytic infiltration in response to estrogen. The results also showed that estrogen produced marked hyperplasia of bronchial smooth muscle cells.

**Conclusion:** Estrogen is the sexual hormones which modulate inflammatory processes in the lungs producing pulmonary inflammatory responses leading to asthma and causes hyperplasia of the bronchiolar smooth muscles.

**Keywords:** Estrogen, Asthma, Bronchiolar smooth muscle, Peri-bronchial lymphocytic infiltration, BALB/c mice

## INTRODUCTION

Birth control methods have been used around the world for many thousands of years. The combined oral contraceptive pill (COCPs) and the minipill are the two most used hormonal contraceptive methods.<sup>1</sup> With the advent of oral contraceptive pills the contraceptive methods have advanced significantly since then. Oral contraception is a highly efficient method of contraception with additional health advantages beyond pregnancy prevention.<sup>2,3</sup>

All COCPs are not same, and brands are different with the amount of estrogen they contain. Estradiol is the estrogen compound used in most oral contraceptives and its derivative form called ethinylestradiol<sup>4</sup> in lower doses (20 microgram and below) which may also reduce side effects.<sup>5</sup>

The beneficial effects of COCP on the reproductive system are most convincing, symptomatic menorrhagia or endometriosis<sup>6</sup>, 50% reduction in risk of endometrial cancer<sup>7</sup> and benign breast disease.<sup>8</sup> In the long term, the risk of cancer of the ovary, uterus, colon and rectum is also reduced.<sup>9</sup> Thus the benefits of oral contraceptives in young healthy women outweigh the side effects which have been more widely publicized.

For many years, estrogen is known to play a role in sexual development,<sup>10,11</sup> however it is now becoming increasingly understood that they have effects beyond the reproductive system. There are two estrogen receptors (ER) types exist: ER- $\alpha$  and ER- $\beta$ , which are expressed in rats<sup>12</sup>, mouse<sup>13</sup> and humans.<sup>14</sup> In addition to the mammalian female and male reproductive systems, ER- $\alpha$  and ER- $\beta$  expression has also been found in the mammary glands, bone, cardiovascular tissues, lung, and brain of female.<sup>10,15</sup> The ER- $\beta$  protein is expressed more in the lungs than ER- $\alpha$ .<sup>16</sup> ER- $\alpha$  and ER- $\beta$  are members of a super family of nuclear hormone receptors, many of which are ligand-activated transcription factors that bind to the promoter region of genes to regulate gene expression.<sup>10</sup>

Both forms of ER, ER- $\alpha$  and ER- $\beta$  are necessary for the development of complete alveolar units in female mice. ER- $\alpha$  promotes normal alveolar density per unit of surface area by ensuring adequate lung differentiation during development. ER- $\beta$  on the other hand, controls extracellular matrix growth, resulting in normal elastic tissue recoil pressure in the lungs.<sup>17</sup> Compared to female and male mice's ERs have lesser impact on the alveolar dimension.<sup>18-20</sup>

Asthma is a chronic airway disease. It is a heterogeneous process and exhibits significant phenotypic variation and affects 300

million people worldwide.<sup>21,22</sup> Variable bronchoconstriction, airway hyper-responsiveness (AHR), airway inflammation, and airway remodeling are the characteristics of asthma.

Epidemiological research on adults has shown that women have a higher prevalence of asthma than men do.<sup>21</sup> Asthma prevalence, morbidity, and mortality are rising in women.<sup>17</sup> Female gender is a significant risk factor for morbidity and mortality in inflammatory lung diseases. It suggests that sex-related hormones might play a key role in asthma disease progression. Additionally, it also reported that estrogen level variations are also responsible for aggravation in asthma in women.<sup>22</sup>

Due to the increasing prevalence of chronic diseases among women globally, understanding the physiologic functions of sex hormones in controlling airway inflammation and other processes associated with asthma is crucial. So therefore, it was planned to measure smooth muscle changes in small bronchioles after sacrificing the mice which have been administered estrogen. The reason for selecting male mice was to rule out the effect of endogenous hormones which are produced in female mice in their normal monthly hormonal fluctuations.

## MATERIAL AND METHODS

The study was carried out in the Physiology Department, Islamabad Medical & Dental College (IMDC), Islamabad. The animal house was in National Institute of Health (NIH), Islamabad and later histological studies were conducted at Pathology Laboratory (IMDC). The Ethical Committee of IMDC approved the experiment. It was laboratory based randomized control trial with the duration of study having 10 months from 1<sup>st</sup> October 2018 to 31<sup>st</sup> July 2019. Sixty BALB/c mice bred in NIH were taken and divided into two groups of thirty each control and interventional group. The controls were given standard laboratory diet and water ad libitum and experimental mice were given standard laboratory diet and estrogen (estradiol valerate) 0.16mg/kg/day once daily by an oral gavage tube for eight weeks. The inclusion criterion was healthy adult male mice of 5-6 weeks age, post puberty, weighing 40-50 grams.

At the end of 8 weeks, animals were anaesthetized by chloroform. Dissection was carried out for removal of lung. Both lungs were removed and placed into 10% formalin. Tissue processing, sectioning and staining procedures were carried out in Histopathology Laboratory of Islamabad Medical & Dental College.

Qualitative and quantitative parameters were observed on light microscope.

**Quantitative parameters of lungs: Hyperplasia of Bronchiolar smooth muscle:** Increase in smooth muscle in the wall of pulmonary blood vessels were measured and estimated for each animal. Using an Olympus digital camera, images were taken from each section (12-mega pixel). To determine the diameter in micrometers, a scale set at 40X was used. Measurements were analyzed and recorded. Results were calculated as average means.

**Qualitative parameters of lungs peri-bronchiolar lymphocytic infiltration:** Peri-bronchiolar lymphocytic infiltration was seen under the microscope and on the basis of the presence of lymphocytes was marked as mild, moderate and severe according to their appearance. Considering less than 25% as mild (low infiltrate <4 cells thick), 25-50% as moderate (medium infiltrate 5-10 cells thick) and more than 50% as Severe (high infiltrate >50% visualized lumen with increased cellularity/thickening).

The data base used was SPSS-24. Chi square test was applied. One way analysis of variance (ANOVA) was used to determine significant difference & Tukey's test for multiple comparisons. It was used to determine significance of changes in lung histology following medication in different groups. p value less than 0.05 was considered statistically significant.

**RESULTS**

In response to estrogen 10% of the total mice had nil, 60% had mild, 30% of the total showed moderate while no severe PBLI was observed in this group (Fig. 1). When the control was compared with estrogens group, highly significant difference was noted (Table 1). Percentage of mice showing nil, mild, moderate estrogen induced peri-bronchial lymphocytic infiltration (Fig. 2).

Different frequencies of BSMH observed in control are shown in Fig. 1. The means of control group A and experimental group's estrogen (B) respectively are given in (Table 2, Fig. 3). Statistically highly significant difference was observed on intergroup comparison of control group with experimental estrogen group (p=0.000). Multiple comparisons of control and estrogen bronchiolar smooth muscle hyperplasia were done by applying post hoc Tukey's Test. It showed highly significant results of control with experimental groups (Table 4).

Table 1: Inter group comparison of control and Estrogen, Bronchiolar Smooth Muscle Hyperplasia

Group A	Group B	P value
.07±0.025	0.54±0.331	0.000

P<0.000 (highly significant)

Table 2: Multiple comparisons of control, estrogen administered groups were documented to observe, bronchiolar smooth muscle hyperplasia

Dependent variable	Group (I)	Group (J)	Mean±SD	P value
Bronchiolar Smooth muscle hyperplasia	Control	Estrogen	.47±.07	.000***
	Estrogen	Control	.47±.07	.000***




Fig. 1: Percentage of mice showing nil, mild, moderate estrogen induced peri-bronchial lymphocytic infiltration

Microscopic study was carried out and by examining the lung section slides under the light microscope, observations were made. H&E stained sections of control group revealed normal structure with normal alveoli & alveolar sac (Fig. 4). Estrogen produced marked hyperplasia of bronchial smooth muscle cells, to orally administered ethinyl estradiol (Fig. 5). Lung sections of experimental estrogen group B showed marked transitions. The lungs not only showed hyperplasia (Fig. 6) but also mild to moderate peri-bronchial lymphocytic infiltration lacking its normal architecture (Fig. 7)




Fig. 2: Different frequencies of smooth muscle hyperplasia observed in control group




Fig. 3: Comparison of mean values of control and estrogen induced bronchiolar smooth muscle hyperplasia (\*\*highly significant)




Fig. 4: Normal alveoli and alveolar sac




Fig. 5: Estrogen induced hyperplasia of 0.6  $\mu\text{m}$ , observed with the help of ocular micrometer at 40X magnification




Fig. 6: Estrogen induced moderate peri-bronchial lymphocytic infiltration




Fig. 7: Estrogen induced moderate peri-bronchial lymphocytic infiltration

## DISCUSSION

Numerous researches have investigated the relation between sex hormones and asthma.<sup>23-26</sup> Sex hormones are vital for maintaining respiratory health and changes in hormone levels may be accountable for aggravation of asthma in women. Hormonal changes in asthmatic women must be monitored carefully.<sup>27</sup> Evidence suggests that at various phases of the female hormonal cycle, both endogenous and exogenous sex hormones affect inflammatory progressions in the lungs and in smooth muscle

tissue.<sup>28</sup> Various studies have found an association between sex hormones and inflammatory responses in the lower airway system, specifically in relation to asthma.<sup>24,26</sup> However, the mechanism remains unclear. Therefore, it is crucial to evaluate the key findings relating sex hormone interactions and comprehend the pathophysiological mechanism of this consortium.

In the present study, group B showed estrogen induced peri-bronchial lymphocytic infiltration which was statistically highly significant as compared to control (group A). Sections of experimental group B (ethinylestradiol exposed mice) showed marked transitions. The lungs not only showed hyperplasia but also mild to moderate peri-bronchial lymphocytic infiltration lacking its normal architecture. As these changes lead to asthma, similar clinical evidence has been suggested by Macsali et al<sup>29</sup> that use of contraceptives is linked with deteriorated lung functions. It is also suggested that using oral contraceptives has a risk factor for asthma development or aggravation.

In a study conducted by Dratva et al<sup>30</sup>, oral contraceptives depicted a shielding outcome, through reducing bronchial hyper-reactivity which goes against our findings. Another study by Nwaru and Sheikh<sup>31</sup>, speculated that hormonal contraceptives decreased asthma exacerbation and the number of episodes need care which is also contradictory to our results. In another study conducted by Lange et al<sup>32</sup>, no relationship was noticed between use of oral contraceptives and asthma.

In the present study, the bronchiolar smooth muscle hyperplasia was observed in both groups. Group B showed marked hyperplasia, to orally administered ethinylestradiol.

Considering that an abnormality of airway smooth muscle is assumed to be the basis of the airway hyper-responsiveness that characterizes asthma and being the second factor under consideration in our research. The pathogenesis of asthma includes the remodelling of the airways. Increased airway smooth muscle mass is a major structural alteration related with airway remodelling. There is emerging evidence that suggests airway smooth muscle cell migration may lead to cellular hyperplasia and, consequently, increased airway smooth muscle mass.<sup>33</sup>

The exact source of these cells remains unidentified. Neighboring airway smooth muscle cells in the bundle, airway myofibroblasts infiltration or circulating hemopoietic progenitor cells contribute to increased airway smooth muscle mass.<sup>33</sup>

Another large epidemiologic study conducted by Tam et al<sup>17</sup> suggested the fact that lung function changes during the menstrual cycle in female airways disease patients but not in healthy women, raises the possibility that circulating estradiol and progesterone are responsible for this phenomenon.

The ability of oestrogen to directly influence the lungs has been proven by Mitchell et al<sup>34</sup> using animal models.

This hormone act through a number of receptors, such as the estrogen receptors ER $\alpha$  and ER $\beta$ . These are also expressed in human lungs leading to the conclusion that sex hormones play a role in lungs development. The mesenchymal and epithelial cells of the lungs also express androgen receptors.

## CONCLUSIONS

Estrogen, modulate inflammatory processes in the lungs and produce pulmonary inflammatory responses which leads to Asthma. It also leads to hyperplasia of the bronchial smooth muscles. So we must be careful prescribing women COCPs or Other oral contraceptives.

## REFERENCES

1. Ammer C. The encyclopedia of women's health: Infobase Publishing; 2009.
2. Group ECW. Non-contraceptive health benefits of combined oral contraception. Human reproduction update. 2005; 11(5): 513-25.
3. Mendoza N, Sanchez-Borrego R. Classical and newly recognised non-contraceptive benefits of combined hormonal contraceptive use in women over 40. Maturitas 2014;78(1):45-50.



4. Golobof A, Kiley J, editors. The current status of oral contraceptives: progress and recent innovations. Seminars in reproductive medicine; Thieme Medical Publishers, 2016
5. Hauck BA, Brown V. A primer on the hormone-free interval for combined oral contraceptives. *Curr Med Res Opin* 2015; 31(10):1941-8.
6. Buggio L, Somigliana E, Barbara G, Frattaruolo MP, Vercellini P. Oral and depot progestin therapy for endometriosis: towards a personalized medicine. *Expert Opin Pharmacotherapy* 2017;18(15): 1569-81.
7. Tschernichovsky R, Goodman A. Risk-reducing strategies for ovarian cancer in BRCA mutation carriers: a balancing act. *Oncologist* 2017;22(4):450-9.
8. Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E. Breast cancer risk factors. *Menopause Rev* 2015;14(3):196.
9. Song J, Jin Z, Han H, Li M, Guo Y, Guo H, et al. Hormone replacement therapies, oral contraceptives, reproductive factors and colorectal adenoma risk: a systematic review and dose-response meta-analysis of observational studies. *Colorectal Disease* 2019.
10. Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA. Reflections on the discovery and significance of estrogen receptor  $\beta$ . *Endocrine Rev* 2005; 26(3): 465-78.
11. Markov GV, Gutierrez-Mazariegos J, Pitrat D, Billas IM, Bonneton F, Moras D, et al. Origin of an ancient hormone/receptor couple revealed by resurrection of an ancestral estrogen. *Sci Adv* 2017;3(3): e1601778.
12. Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. *Proc Nat Acad Sci* 1996; 93(12): 5925-30.
13. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor  $\beta$ . *Molecular Endocrinol* 1997; 11(3): 353-65.
14. Barton M, Filardo E, Lolait S, Thomas P, Maggiolini M, Prossnitz, ER. Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. *J Steroid Biochem Molecular Biol* 2018; 176: 4-15.
15. Cooke PS, Nanjappa MK, Ko C, Prins GS, Hess RA. Estrogens in male physiology. *Physiological Rev* 2017;97(3):995-1043.
16. Ivanova MM, Mazhawidza W, Dougherty SM, Minna JD, Klinge CM. Activity and intracellular location of estrogen receptors  $\alpha$  and  $\beta$  in human bronchial epithelial cells. *Molecular Cellular Endocrinol* 2009;305(1-2):12-21.
17. Tam A, Morrish D, Wadsworth S, Dorscheid D, Man SP, Sin DD. The role of female hormones on lung function in chronic lung diseases. *BMC Women's Health* 2011;11(1):24.
18. Massaro D, Massaro GD. Estrogen receptor regulation of pulmonary alveolar dimensions: alveolar sexual dimorphism in mice. *Am J Physiol Lung Cell Mol Physiol* 2006; 290: L866-70.
19. Carey MA, Card JW, Voltz JW, Germolec DR, Korach KS, Zeldin DC. The impact of sex and sex hormones on lung physiology and disease: lessons from animal studies. *Am J Physiol Lung Cellular Mol Physiol* 2007;293(2):L272-8.
20. Cephus JY, Stier MT, Fuseini H, Yung JA, Toki S, Bloodworth MH, Zhou W, Goleniewska K, Zhang J, Garon SL, Hamilton RG. Testosterone attenuates group 2 innate lymphoid cell-mediated airway inflammation. *Cell Reports* 2017; 21(9) :2487-99.
21. Bateman ED, Hurd S, Barnes P, Bousquet J, Drazen J, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. *Eur Resp J* 2008;31(1):143-78.
22. Baldaçara RPdC, Silva I. Association between asthma and female sex hormones. *Sao Paulo Med J* 2017; 135(1): 4-14.
23. Barr RG, Wentowski CC, Grodstein F, Somers SC, Stampfer MJ, Schwartz J, et al. Prospective study of postmenopausal hormone use and newly diagnosed asthma and chronic obstructive pulmonary disease. *Arch Intern Med* 2004; 164(4): 379-86.
24. Matteis M, Polverino F, Spaziano G, Roviezzo F, Santoriello C, Sullo N, et al. Effects of sex hormones on bronchial reactivity during the menstrual cycle. *BMC Pulmonary Med* 2014;14(1):108.
25. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. *Human Reprod Update* 2005; 11(4):411-23.
26. Kynyk JA, Mastronarde JG, McCallister JW. Asthma, the sex difference. *Curr Opin Pulmonary Med* 2011;17(1):6-11.
27. KARPEL JP, WAIT JL. Asthma in women, Part 3: Perimenstrual asthma, effects of hormone therapy. *J Crit Illness* 2000; 15(5):265-.
28. Salam MT, Wenten M, Gilliland FD. Endogenous and exogenous sex steroid hormones and asthma and wheeze in young women. *J Allergy Clin Immunol* 2006; 117(5):1001-7.
29. Macsali F, Real FG, Omenaas ER, Bjorge L, Janson C, Franklin K, et al. Oral contraception, body mass index, and asthma: a cross-sectional Nordic-Baltic population survey. *J Allergy Clin Immunol* 2009;123(2):391-7.
30. Dratva J, Schindler C, Curjurić I, Stolz D, Macsali F, Gomez FR, et al. Perimenstrual increase in bronchial hyperreactivity in premenopausal women: results from the population-based SAPALDIA 2 cohort. *J Allergy Clin Immunol* 2010;125(4):823-9.
31. Nwaru BI, Sheikh A. Hormonal contraceptives and asthma in women of reproductive age: analysis of data from serial national Scottish Health Surveys. *J Royal Soc Med* 2015;108(9):358-71.
32. Lange P, Parner J, Prescott E, Ulrik CS, Vestbo J. Exogenous female sex steroid hormones and risk of asthma and asthma-like symptoms: a cross sectional study of the general population. *Thorax* 2001; 56(8):613-6.
33. Salter B, Pray C, Radford K, Martin JG, Nair P. Regulation of human airway smooth muscle cell migration and relevance to asthma. *Resp Res* 2017; 18(1): 156